Nature exhibits a unique beauty that is both recognized and integrated into human practices globally. Annona squamosa Linn., commonly known as “sweet sugar,” is a small medicinal shrub cultivated for its fruits. This species is widely distributed across Asia, Africa, North and South America, and Brazil. Traditionally, it has been used for its antidiabetic, antihypertensive, insecticidal, and antimicrobial properties. This article is based on the literature review collected from various sources such as Scopus, Sci-Hub, PubMed, Google Scholar, Science Direct, and SciFinder. The literature review reveals that A. squamosa possesses numerous promising pharmacological activities due to its rich array of active phytoconstituents. This review provides essential knowledge for future research, guiding investigators in exploring the plant’s pharmacological activities, isolating bioactive fractions, and implementing these findings in the management of various diseases.

Background: Hyperlipidemia is a common precursor to cardiovascular diseases, necessitating effective intervention. This study explores the potential of a bioactive fraction derived from Kalanchoe pinnata leaf, a less-explored natural source, for its antihyperlipidemic properties. Objectives: The primary objectives of this research are to isolate and assess the bioactive fraction from Kalanchoe pinnata leaves extract for its antihyperlipidemic attributes using a murine model. The study also aims to characterize the fraction and investigate its interactions with hyperlipidemia-related proteins. Materials and Methods: Kalanchoe pinnata leaves were extracted and fractionated via flash chromatography. Isolated fractions underwent phytochemical, antioxidant, and enzyme inhibition assays in vitro. In vivo, selected fractions were tested in Triton WR-1339-induced hyperlipidemic mice. Fraction F2, which exhibits the most potent activity, was characterized using HPTLC MS/MSⁿ chromatography. Molecular docking studies explored interactions between F2 compounds and hyperlipidemia-related proteins. Results: Fraction F2 displayed significant in vivo antihyperlipidemic activity, with observable morphological changes in mice. HPTLC MS/MSⁿ identified four major compounds in F2, while docking studies revealed potential interactions with hyperlipidemia-related proteins. Conclusion: This study underscores F2’s potential as a potent antihyperlipidemic agent sourced from Kalanchoe pinnata leaves. The identified compounds hold promise for further research in hyperlipidemia therapy development, emphasizing the therapeutic potential of natural Kalanchoe pinnata compounds for managing hyperlipidemia and related cardiovascular conditions.